

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449	Atty Docket No. 116566-002	Application No. 10/526,127
	Applicant Campochiaro et al.	
	Filing Date 28 February 2005	Group Unassigned

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	6,267,954	7/31/01	Abitbol et al.			

FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 0193897	12/13/01	WIPO				
	WO 0230902	4/18/02	WIPO				

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Mori, Katsuko et al., "Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secreted endostatin," American Journal of Pathology, Vol. 159, No. 1, July 2001, pp. 313-320.
	Ohno-Matsui, Kyoko et al., "Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment," American Journal of Pathology, Vol. 160, No. 2, February 2002, pp. 711-719.
	Ozaki, H. et al., "Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization," American Journal of Pathology, Vol. 156, No. 2, February 2000, pp. 697-707.
	Takahashi, Kyoichi et al., "Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment," FASEB Journal, Vol. 17, No. 8, May 2003, pp. 896-898.

Examiner: /Scott Long/ (02/24/2009)	Date Considered: 02/24/2009
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	